Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors.

Cartilage tumors have a special angiogenic phenotype, with blood vessels arranged predominantly in pericartilage fibrous septa and relatively low microvessel density (MVD), except in dedifferentiated chondrosarcomas. To further elucidate angiogenesis in cartilage tumors, we used double-labeling immunohistochemistry to determine microvessel pericyte coverage index (MPI) and proliferating capillary index (PCI), referring to blood vessel maturation and angiogenic activity in enchondromas, conventional chondrosarcomas, and dedifferentiated chondrosarcomas. Altogether, we found high MPIs (>70%) especially in dedifferentiated chondrosarcomas but without a correlation to the grade of malignancy. PCI was significantly higher in conventional chondrosarcomas grades II and III than in enchondromas, chondrosarcomas grade I, and dedifferentiated chondrosarcomas. Thus, PCI positively correlated with the previously reported differential expression of vascular endothelial growth factor (VEGF)-A in cartilage tumors. Altogether, cartilage tumors exhibit a heterogeneous but predominantly mature angiogenic phenotype with differential proliferative activity.

[1]  T Kobayashi,et al.  Hypoxia in cartilage: HIF-1alpha is essential for chondrocyte growth arrest and survival. , 2001, Genes & development.

[2]  Akiyoshi Uemura,et al.  Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. , 2002, The Journal of clinical investigation.

[3]  R. Poon,et al.  Clinical Implications of Angiogenesis in Cancers , 2006, Vascular health and risk management.

[4]  E. Voest,et al.  Are tumours angiogenesis‐dependent? , 2004, The Journal of pathology.

[5]  S. Sel,et al.  ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma. , 2007, Human pathology.

[6]  Michael D Feldman,et al.  Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. , 2003, The American journal of pathology.

[7]  G. Batist,et al.  Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. , 2003, Clinical lung cancer.

[8]  L. Ellis,et al.  Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Terek,et al.  Pathologic Neovascularization in Cartilage Tumors , 2002, Clinical orthopaedics and related research.

[10]  G. Ayala,et al.  Microvasculature and VEGF expression in cartilaginous tumors. , 2000, Human pathology.

[11]  J. Block,et al.  Hypoxia induces HIF‐1α and VEGF expression in chondrosarcoma cells and chondrocytes , 2004 .

[12]  H. Hammes,et al.  Endothelial survival factors and spatial completion, but not pericyte coverage of retinal capillaries, determine vessel plasticity , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  米永 吉邦.  Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients , 2007 .

[14]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[15]  U. Schlötzer-Schrehardt,et al.  Pericyte recruitment in human corneal angiogenesis: an ultrastructural study with clinicopathological correlation , 2003, The British journal of ophthalmology.

[16]  S. Sel,et al.  Differential expression of VEGF‐A and angiopoietins in cartilage tumors and regulation by interleukin‐1β , 2006, Cancer.

[17]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[18]  Stephen B. Fox,et al.  COMMENTARY Tumour angiogenesis and prognosis , 1997, Histopathology.

[19]  W. Stallcup,et al.  Early Contribution of Pericytes to Angiogenic Sprouting and Tube Formation , 2004, Angiogenesis.

[20]  H. Augustin,et al.  Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. , 2000, Cancer research.

[21]  G. Batist,et al.  Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  P. Hahnfeldt,et al.  Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.

[23]  M. Glimcher,et al.  Systemic hypoxia alters gene expression levels of structural proteins and growth factors in knee joint cartilage. , 2005, Biochemical and biophysical research communications.

[24]  M. Hochberg,et al.  Erosive Osteoarthritis , 2010 .

[25]  Debra L Barton,et al.  Evaluation of shark cartilage in patients with advanced cancer , 2005, Cancer.

[26]  S. Fox.  Tumour angiogenesis and prognosis. , 1997, Histopathology.

[27]  D. Walsh,et al.  Osteoarthritis, angiogenesis and inflammation. , 2005, Rheumatology.

[28]  D. Gingras,et al.  Shark Cartilage Extracts as Antiangiogenic Agents: Smart Drinks or Bitter Pills? , 2004, Cancer and Metastasis Reviews.

[29]  Dai Fukumura,et al.  Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. , 2007, Microvascular research.

[30]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.